10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC

FNY Investment Advisers LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,200 shares of the company’s stock, valued at approximately $1,073,000.

Several other institutional investors and hedge funds also recently bought and sold shares of MRK. Chemung Canal Trust Co. boosted its holdings in Merck & Co., Inc. by 21.1% in the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after purchasing an additional 13,285 shares in the last quarter. First Pacific Financial raised its holdings in Merck & Co., Inc. by 14.7% during the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co lifted its position in shares of Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after buying an additional 18,187 shares during the last quarter. Caxton Associates LLP lifted its position in shares of Merck & Co., Inc. by 23.3% in the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after buying an additional 7,458 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its stake in shares of Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Michael Williams sold 5,000 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the transaction, the executive vice president owned 30,838 shares of the company’s stock, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price target for the company from $82.00 to $130.00 in a report on Thursday, December 18th. UBS Group lifted their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, Barclays started coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European approval expands KEYTRUDA use to a platinum‑resistant ovarian cancer population (PD‑L1 CPS ≥1). This label adds a new, high‑need indication and could incrementally lift oncology sales in Europe if uptake is steady; approval reduces regulatory uncertainty for the combo in that market. Merck granted EU approval of Keytruda combo in ovarian cancer
• Positive Sentiment: European Commission press release confirming KEYTRUDA + paclitaxel ± bevacizumab approval for PD‑L1‑positive, platinum‑resistant recurrent ovarian carcinoma — reinforces the commercial significance of the approval and the company’s oncology momentum in EU markets. European Commission Approves KEYTRUDA combo
• Positive Sentiment: Merck reported strong Phase 3 results for an oral PCSK9 candidate (enlicitide decanoate) — if confirmed through regulatory paths, an oral PCSK9 could be a major commercial opportunity in lipid management and compete with injectables, implying material long‑term upside to cardiovascular franchise revenue. Merck Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Initiation of a pivotal Phase 2b/3 trial for MK‑8748 (Tiespectus) in neovascular AMD shows Merck advancing a novel bispecific Tie2 agonist/VEGF inhibitor into registrational testing — de‑risks a promising ophthalmology program and could add a new specialty product if successful. Merck Announces Initiation of Pivotal Phase 2b/3 Trial
• Positive Sentiment: Royal Bank of Canada assigned an Outperform rating — analyst upgrades/support can buoy sentiment and buying interest, especially when coupled with pipeline news and recent beats. Merck Earns Outperform Rating from RBC
• Neutral Sentiment: Merck released detailed Phase 2 CADENCE data (WINREVAIR) — more granular data helps investors assess clinical profile and commercial potential, but Phase 2 detail typically moves shares less than registrational results unless outcomes are transformational. Merck Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck completed the acquisition of JSR Life Sciences’ chromatography business — broadens manufacturing/service capabilities (note: some headlines refer to Merck KGaA; confirm scope). Strategic but not immediately revenue‑moving for MRK’s core drug sales. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Neutral Sentiment: Sector commentary: Lilly warned against locking pricing‑deal rules into law, citing innovation risk — a reminder of policy/regulatory uncertainty that can affect the whole pharma sector, including MRK, but it’s not a company‑specific development. Lilly Pushes Back on Making Drug Price Deals Permanent

Merck & Co., Inc. Price Performance

NYSE MRK opened at $120.62 on Friday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The stock has a market capitalization of $298.21 billion, a PE ratio of 16.57, a P/E/G ratio of 2.44 and a beta of 0.26. The stock has a 50-day simple moving average of $117.47 and a 200 day simple moving average of $102.80.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.